Article

Aging, glaucomatous eyes may differ in rate of axon loss

San Diego-The rate of change in axon loss, not the location of the damage, most likely differentiates an aging eye from a glaucomatous eye, according to recent research, said Claude F. Burgoyne, MD, holder of the Van Buskirk Chair for Ophthalmic Research, Devers Eye Institute, Portland, OR.

San Diego—The rate of change in axon loss, not the location of the damage, most likely differentiates an aging eye from a glaucomatous eye, according to recent research, said Claude F. Burgoyne, MD, holder of the Van Buskirk Chair for Ophthalmic Research, Devers Eye Institute, Portland, OR.

Such a differentiation could help ophthalmologists determine whether axon loss in an eye with glaucoma is due to aging or due to the disease and whether an IOP-lowering intervention might slow the rate of change.

“Whether it’s glaucoma or aging, the rate of change is essential to determine,” however, he said. “There’s a growing movement to do rate-of-change characterization for both structure and visual field.”

A growing body of literature is examining the overlap of disc and field change in patients with glaucoma and “age-matched normal” patients followed over time for progression, he said.

“Increasingly, the [glaucoma-related] data will be overlaid onto age-matched normals over time so that you can estimate the rate of change in your parameters relative to age-matched normals,” Dr. Burgoyne predicted,

When deciding whether to treat IOP in an aged patient with slowly progressing disease, he said, “all of our current parameters will pertain,” including life expectancy, the risks of lowering IOP, and whether an age-related rate of axon loss affects central vision.

“However, if the pathophysiology of aging and glaucoma can be shown to be linked…it’s reasonable to consider that lowering IOP can influence the rate of [progression previously attributed to aging],” Dr. Burgoyne concluded.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
© 2025 MJH Life Sciences

All rights reserved.